Journal Browser

► Journal Browser

Special Issue Editors

Special Issue Information

Dear Colleagues,

Urogenital cancers include tumours of the kidney and bladder, and, in men, of the prostate and testicle pose considerable challenges to the urologist. Recent advances in molecular diagnosis and precision medicine provide more therapeutic strategies and favourable prognoses in patients with urogenital cancers. This Special Issue of the Journal of Personalized Medicine aims to explore the latest innovative molecular findings or clinical experience to provide more evidence to support further clinical trials. Studies of basic science, translational, clinical and population-based approaches are encouraged to submit contributions. Our goal is to demonstrate the scientific advances in the field of urogenital cancers and pave the way towards personalized medicine or diagnosis. Both original research and review articles are welcome.

Dr. Wen-Wei Sung
Dr. Jian-Ri Li
Dr. Chih-Jung Chen
Dr. Cheng-Kuang Yang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

kidney cancer
bladder cancer
prostate cancer
testicular cancer
upper tract urothelial carcinoma
retroperitoneal tumor
immunotherapy
target therapy
precision medicine

Published Papers (2 papers)

Download All Papers

Research

Jump to: Other

13 pages, 675 KiB

Open AccessArticle

Interplay between Comprehensive Inflammation Indices and Redox Biomarkers in Testicular Germ-Cell Tumors

by Uros Bumbasirevic, Nebojsa Bojanic, Tatjana Simic, Bogomir Milojevic, Marko Zivkovic, Tijana Kosanovic, Boris Kajmakovic, Aleksandar Janicic, Otas Durutovic, Milan Radovanovic, Veljko Santric, Milica Zekovic and Vesna Coric

J. Pers. Med. 2022, 12(5), 833; https://0-doi-org.brum.beds.ac.uk/10.3390/jpm12050833 - 20 May 2022

Cited by 5 | Viewed by 2838

Abstract

Sustained and dysregulated inflammation, concurrent tumor-induced immune suppression, and oxidative stress are profoundly involved in cancer initiation, presentation, and perpetuation. Within this prospective study, we simultaneously analyzed the preoperative indices of systemic inflammatory response and the representative byproducts of oxidative DNA, protein, and lipid damage with the aim of evaluating their clinical relevance among patients diagnosed with testicular germ-cell tumors (GCT). In the analytical cohort (n = 88, median age 34 years), neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and C-reactive protein (CRP) were significantly altered in patients with a higher tumor stage (p < 0.05). Highly suggestive correlations were found between NLR, dNLR, and SII and modified nucleoside 8-OHdG. CRP and albumin-to-globulin ratio (AGR) significantly correlated with thiols group level and maximal tumor dimension (p < 0.05). Based on receiver operating characteristic (ROC) curve analyses, all the evaluated pre-orchiectomy inflammation markers demonstrated strong performance in predicting metastatic disease; optimal cut-off points were determined for each indicator. Although further large-scale studies are warranted, inflammatory and redox indices may both complement the established tumor markers and standard clinicopathological prognostic variables and contribute to enhanced personalized risk-assessment among testicular GCT patients. Full article

(This article belongs to the Special Issue Precision Medicine and Molecular Diagnosis for Urogenital Cancer)

► Show Figures

Figure 1

Other

Jump to: Research

8 pages, 1096 KiB

Open AccessSystematic Review

The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis

by Alessandro Rizzo, Matteo Santoni, Veronica Mollica, Angela Dalia Ricci, Concetta Calabrò, Antonio Cusmai, Gennaro Gadaleta-Caldarola, Gennaro Palmiotti and Francesco Massari

J. Pers. Med. 2022, 12(5), 842; https://0-doi-org.brum.beds.ac.uk/10.3390/jpm12050842 - 20 May 2022

Cited by 7 | Viewed by 2086

Abstract

Background. Immune checkpoint inhibitors (ICIs) have recently represented a breakthrough in urothelial carcinoma (UC). Proton pump inhibitors (PPIs) are routinely used for extended time periods in UC patients, with these agents having potentially and frequently undervalued effects on ICIs efficacy. Methods. We performed a meta-analysis aimed at investigating the impact of concomitant PPI administration on progression-free survival (PFS) and overall survival (OS) among patients receiving immunotherapy for metastatic UC. Results. Two studies encompassing a total of 1015 patients were included. The pooled Hazard Ratios (HRs) for OS and PFS were 1.55 (95% CI, 1.31–1.84) and 1.43 (95% CI, 1.23–1.66), respectively, suggesting that the administration of PPIs was negatively associated with PFS and with OS in UC patients treated with ICIs. Conclusions. The current meta-analysis represents the first study to provide a systematic evaluation of the impact of concomitant PPI use in UC patients treated with ICIs. Further studies are warranted on this topic to clarify the relationship between gut microbiome, antiacid exposure, and cancer immunotherapy. In the current era of medical oncology, progress in this setting will require the collaboration of basic science and clinical research to optimize systemic treatment and to improve the outcomes of UC patients receiving ICIs. Full article

(This article belongs to the Special Issue Precision Medicine and Molecular Diagnosis for Urogenital Cancer)

► Show Figures